Q: Which of the following equations correctly represents the calculation of the International Normalized Ratio (INR) used to monitor warfarin therapy?

$$\text{INR} = \left( \frac{\text{Patient PT}}{\text{Mean Normal PT}} \$$right)^{\text{ISI}$$}$$

Question 1

A 5.5-year-old boy experienced severe respiratory depression after a single dose of tramadol post-adenotonsillectomy. PGx testing revealed a CYP2D6*2X2/*2 genotype. Which of the following best explains the mechanism behind his adverse reaction?

Accepted Answer

He was an Ultra-rapid Metabolizer for CYP2D6, resulting in excessive conversion of tramadol to O-desmethyltramadol, a potent mu-opioid agonist.

Question 2

In the adolescent ADHD case, the patient was found to be a Poor Metabolizer for CYP2D6. Which of the following would most likely occur if he were prescribed a medication primarily metabolized by CYP2D6?

Accepted Answer

The medication would accumulate, increasing the risk of side effects or toxicity.

Question 3

A patient with a CYP2C9*1/*3 genotype is prescribed warfarin. Which of the following best describes the expected pharmacokinetic effect?

Accepted Answer

Decreased enzymatic activity, resulting in higher warfarin plasma concentrations and increased bleeding risk.

Question 4

Which of the following best illustrates the difference between an adverse drug reaction (ADR) and a drug allergy in the context of pharmacogenomics?

Accepted Answer

A drug allergy is a specific type of ADR involving the immune system, while pharmacogenomic variants typically cause non-immune ADRs.

Question 5

A patient is prescribed escitalopram, which is metabolized by CYP2C19 and CYP3A4. If the patient is an Extensive Metabolizer for both enzymes, what is the most likely clinical implication?

Accepted Answer

Escitalopram will be metabolized at a normal rate, likely resulting in expected therapeutic effects.

Question 6

Which of the following equations correctly represents the calculation of the International Normalized Ratio (INR) used to monitor warfarin therapy?

Accepted Answer

$$	ext{INR} = \left( \frac{	ext{Patient PT}}{	ext{Mean Normal PT}} \$$right)^{	ext{ISI}$$}$$

Question 7

A patient with a mutation in the MTHFR gene resulting in low monoamine and catecholamine production is most likely to experience which of the following?

Accepted Answer

Decreased synthesis of neurotransmitters, potentially contributing to mood and behavioral disorders.

Question 8

In the warfarin case, the patient’s INR was found to be 9. What is the most likely clinical consequence of such an elevated INR?

Accepted Answer

Increased risk of bleeding, including potentially fatal hemorrhage.

Question 9

Which of the following best describes the role of the CYP2D6 enzyme in the metabolism of tramadol?

Accepted Answer

CYP2D6 converts tramadol to O-desmethyltramadol, which has a much higher affinity for mu-opioid receptors.

Question 10

A patient with a deleterious mutation in the 5HT2C serotonin receptor gene is most likely to experience which of the following effects?

Accepted Answer

Reduced receptor affinity for serotonin, potentially diminishing the efficacy of serotonergic medications.

Question 11

Which of the following best explains why pharmacogenomic (PGx) testing is important before prescribing warfarin?

Accepted Answer

PGx testing can identify patients with reduced metabolism, who are at higher risk for bleeding complications.

Question 12

A patient is found to be an Ultra-rapid Metabolizer for CYP2D6. Which of the following drugs would most likely require dose adjustment or alternative therapy to avoid toxicity?

Accepted Answer

A prodrug activated by CYP2D6, such as codeine or tramadol.

Question 13

Which of the following statements best describes the impact of non-genetic factors on pharmacogenomic testing results?

Accepted Answer

Non-genetic factors, such as diet and drug interactions, can influence drug response even when genetic testing is performed.

Question 14

A patient with a history of poor response to multiple psychotropic medications is found to be a Poor Metabolizer for CYP2D6 and has a mutation in MTHFR. Which of the following best explains the rationale for switching to escitalopram, metabolized by CYP2C19 and CYP3A4?

Accepted Answer

Escitalopram is not affected by CYP2D6 metabolism, so the patient can metabolize it normally.

Question 15

Which of the following best describes the clinical utility of PGx testing in preventing adverse drug reactions?

Accepted Answer

PGx testing can identify genetic variants that increase the risk of toxicity or therapeutic failure, allowing for personalized drug selection and dosing.

Question 16

A patient with a wild-type VKORC1 gene and a CYP2C9*3 allele is prescribed warfarin. Which of the following is the most appropriate clinical action?

Accepted Answer

Initiate warfarin at a lower dose and monitor INR closely.

Question 17

Which of the following best explains why the child in the tramadol case experienced a life-threatening event after a standard dose?

Accepted Answer

He was an Ultra-rapid Metabolizer for CYP2D6, resulting in rapid formation of a highly potent metabolite.

Question 18

Which of the following is a limitation of pharmacogenomic testing in clinical practice?

Accepted Answer

It cannot account for non-genetic factors such as drug interactions, diet, or organ function.

Clinical Applications and Limitations of Pharmacogenomic Testing

Study Guide - Practice Questions

Study Guide - Flashcards